StockNews.com Begins Coverage on InspireMD (NYSE:NSPR)

Analysts at StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a research note issued to investors on Monday. The brokerage set a “sell” rating on the stock.

Separately, Piper Sandler restated an “overweight” rating and issued a $4.50 price objective on shares of InspireMD in a research report on Tuesday, September 17th.

InspireMD Stock Performance

Shares of NSPR opened at $2.78 on Monday. The company has a market capitalization of $69.31 million, a P/E ratio of -3.66 and a beta of 0.90. The business’s 50-day moving average is $2.78 and its two-hundred day moving average is $2.51. InspireMD has a fifty-two week low of $1.81 and a fifty-two week high of $3.85.

InspireMD (NYSE:NSPR) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). The company had revenue of $1.74 million during the quarter, compared to analysts’ expectations of $1.74 million. InspireMD had a negative return on equity of 62.02% and a negative net margin of 388.67%. During the same quarter in the prior year, the company posted ($0.24) EPS. Analysts forecast that InspireMD will post -0.82 EPS for the current year.

Institutional Trading of InspireMD

A hedge fund recently raised its stake in InspireMD stock. Rosalind Advisors Inc. raised its position in InspireMD, Inc. (NYSE:NSPR) by 266.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,513,641 shares of the company’s stock after purchasing an additional 1,827,579 shares during the quarter. InspireMD accounts for approximately 4.6% of Rosalind Advisors Inc.’s portfolio, making the stock its 8th largest position. Rosalind Advisors Inc. owned about 10.08% of InspireMD worth $6,272,000 at the end of the most recent reporting period. Institutional investors own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.